Michail_Petrov-96/iStock by way of Getty Pictures
- SAB Biotherapeutics (NASDAQ:SABS) pronounces a brand new identify, SAB BIO, and a brand new visible identification, efficient instantly.
- The brand new model identification goals to align with its mission to deal with and stop immune and autoimmune issues utilizing its distinctive immunotherapy platform.
- SABS plans to rebrand forward of a poster presentation on the American Diabetes Affiliation’s 84th Scientific Periods. The convention will likely be held in Florida from June 21 by June 24.
- The rebranding features a new identify, emblem mark, and web site updates to mirror the corporate’s strategic evolution; nonetheless, the inventory image will stay SABS.
- Moreover, the corporate additionally reaffirmed its outlook for fiscal 12 months 2024, as beforehand disclosed in first quarter earnings, and in addition confirmed its upcoming milestones, together with a topline knowledge readout from its Section 1 research of its lead candidate, SAB-142.
